*Refresh the page if the below document does not appear.
In the new year, reinventing and innovating will be the main mantras of the Indian pharma industry. The industry also emerging as the ‘pharmacy of the world’ looks to move forward from volume to value leadership amidst the rising pricing pressures and inflation issues.
The Maiden Pharma’s cough syrup case has been bought to light again in Gambia. According to BBC, a parliamentary committee in Gambia has suggested “prosecution of an Indian manufacturer of cough syrups suspected of killing at least 70 children in the West African country” .
Recently, a change in FDA’s cancer drug practice was observed when GSK pulled an accelerated approval for the multiple myeloma drug Blenrep at the request of the FDA just 15 days after revealing a confirmatory trial failure. The fact showed a major makeover happening in the FDA’s oncology department.
Global Drugmaker Lupin Pharma on Wednesday declared that it has received approval from the US FDA for its Abbreviated New Drug Application (ANDA) for Brivaracetam Tablets, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg strength.
On Wednesday, shares of Glenmark Pharmaceuticals rose nearly 6% in intraday trade, in contrast with the observations before the launch of Zita‐PioMet, the country’s first triple fixed-dose combination for high insulin‐resistant type 2 diabetes.
As the number of Covid cases is rising in China, it is making some Indian Pharma firms fear the disruption in API (Active Pharmaceutical Ingredient) supplies in India, as over 65% of API is imported from the neighboring countries.
Glenmark pharmaceuticals Limited has
launched the first-of-its-kind triple fixed-dose
combination of Teneligliptin with Pioglitazone,
and Metformin in India. This FDC has come to
the market with a brand name of Zita-PioMet
containing the three drugs in a sustained
release (SR) formulation.
If you don’t already have an account click the button below to create your account.Create New Account
Please update your profile to keep using the website